Tilray (TLRY) AI Stock Analysis

• Market Cap: $1.89B
• Dividend Yield: N/A
• Average Volume (3M): 84.12M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.59
• Revenue Growth: 2.31%
• EPS Growth: -726.17%
• Country: US
• Employees: 2,650
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.00
• Shares Outstanding: 1,122,863,200
• 10 Day Avg. Volume: 119,861,618
• 30 Day Avg. Volume: 84,120,582
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.18
• Price to Sales (P/S): 0.34
• P/FCF Ratio: -2.97
• Enterprise Value/Market Cap: 0.80
• Enterprise Value/Revenue: 1.39
• Enterprise Value/Gross Profit: 4.83
• Enterprise Value/Ebitda: -0.51
• 1Y Price Target: $1.37
• Price Target Upside: -11.04% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 6

• Rating: 51 Neutral
• Price Target: $2.00 ▲(29.87% Upside)

Tilray's overall stock score is primarily impacted by its weak financial performance, with significant losses and liquidity issues. Despite positive technical momentum, the negative valuation metrics and ongoing financial challenges weigh heavily on the score.

Positive Factors

International Expansion

Tilray's international expansion, particularly in Germany, enhances its market position and diversifies revenue streams, supporting long-term growth.

Balance Sheet Strength

A strong balance sheet with low leverage and substantial cash reserves provides financial stability and flexibility for future investments.

Revenue Growth

Consistent revenue growth, driven by key segments, indicates robust demand and effective strategic execution, supporting long-term business prospects.

Negative Factors

Declining Profit Margins

Decreasing profit margins can pressure profitability, indicating potential challenges in cost management and pricing power in core segments.

Cash Flow Issues

Poor cash generation and liquidity issues may limit Tilray's ability to invest in growth initiatives and manage financial obligations effectively.

Permitting Delays

Regulatory delays in key markets can hinder expansion efforts and revenue growth, impacting Tilray's ability to capitalize on international opportunities.

Tilray Business Overview & Revenue Model

Company Description

Tilray Brands, Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company operates through four segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. It offers medical and adult-use cannabis products, including GMP-certified flowers, oils, vapes, edibles, and topicals; purchases and resells pharmaceutical and wellness products; and produces, markets, sells, and distributes beverage alcohol products, and hemp-based food and other wellness products. The company offers its products under the Tilray, Aphria, Broken Coast, Symbios, B!NGO, The Batch, P'tite Pof, Dubon, Good Supply, Solei, Chowie Wowie, Canaca, RIFF, SweetWater, Breckenridge Distillery, Alpine Beer Company, and Green Flash brands. It sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. Tilray Brands, Inc. is headquartered in Leamington, Canada.

How the Company Makes Money

Tilray generates revenue primarily through the sale of cannabis products, including dried flower, oils, and edibles, which are sold to both medical and recreational consumers. The company has established key revenue streams through its direct-to-consumer sales, partnerships with distributors and retailers, and international exports of medical cannabis products. Additionally, Tilray has formed strategic alliances with other companies in the cannabis and pharmaceutical sectors, which enhance its market reach and product offerings. The company's ongoing focus on research and development also positions it to capitalize on emerging trends in the cannabis market, contributing to its earnings potential.

Tilray Financial Statement Overview

Summary

Tilray's financial performance is weak, with significant losses and declining revenue. The income statement shows negative net profit margins and revenue contraction. The balance sheet indicates low leverage but negative returns, and cash flow analysis reveals liquidity issues with negative cash flows.

Income Statement

Tilray's income statement reveals significant challenges, with negative net profit margins and declining revenue growth. The TTM data shows a gross profit margin of 28.77%, but the net profit margin is deeply negative at -278.12%, indicating substantial losses. Revenue growth is negative, suggesting a contraction in sales. Overall, the company is struggling with profitability and growth.

Balance Sheet

The balance sheet shows a relatively low debt-to-equity ratio of 0.15 in the TTM period, indicating conservative leverage. However, the return on equity is negative, reflecting ongoing losses. The equity ratio is not provided, but the available data suggests financial stability in terms of debt management, albeit with profitability concerns.

Cash Flow

Cash flow analysis highlights significant issues, with negative operating and free cash flows. The TTM data shows a free cash flow growth rate of -31.63%, indicating worsening cash generation. The operating cash flow to net income ratio is negative, reflecting poor cash conversion. Overall, the cash flow situation is concerning, with limited liquidity.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.08B	1.13B	1.07B	844.72M	792.12M	619.67M
Gross Profit	311.03M	330.11M	304.33M	197.95M	147.26M	148.77M
EBITDA	-2.97B	-2.92B	-99.25M	-1.72B	-310.61M	-297.41M
Net Income	-3.01B	-3.00B	-333.80M	-1.96B	-601.05M	-443.75M
Balance Sheet
Total Assets	2.08B	2.90B	5.91B	5.92B	6.87B	7.27B
Cash, Cash Equivalents and Short-Term Investments	264.83M	351.78M	354.98M	604.16M	524.29M	589.77M
Total Debt	231.29M	451.09M	527.75M	794.89M	786.36M	1.13B
Total Liabilities	561.99M	860.49M	1.22B	1.44B	1.27B	1.88B
Stockholders Equity	1.54B	2.07B	4.69B	4.47B	5.55B	5.38B
Cash Flow
Free Cash Flow	-119.70M	-174.98M	-81.96M	-17.37M	-266.39M	-100.93M
Operating Cash Flow	-83.01M	-129.81M	-42.11M	10.65M	-223.45M	-53.99M
Investing Cash Flow	28.48M	-64.11M	174.88M	-384.04M	-27.14M	55.67M
Financing Cash Flow	120.54M	183.20M	-102.45M	94.50M	161.60M	150.09M

Tilray Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.54
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TLRY, the sentiment is Positive. The current price of 1.54 is below the 20-day moving average (MA) of 1.55, above the 50-day MA of 1.31, and above the 200-day MA of 0.84, indicating a neutral trend. The MACD of 0.13 indicates Positive momentum. The RSI at 51.33 is Neutral, neither overbought nor oversold. The STOCH value of 11.93 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TLRY.

Tilray Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SNDL	59 Neutral	$638.35M	―	-8.30%	―	0.70%	15.62%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TLRY	51 Neutral	$1.89B	―	-85.59%	―	2.31%	-726.17%
IMCC	41 Neutral	$10.34M	―	-36.94%	―	2.17%	88.34%

Tilray Corporate Events

Tilray Completes Debt-for-Equity Exchange Transaction

Tilray Brands, Inc. has completed a private debt-for-equity exchange transaction with an unrelated party. The company issued over 12.5 million shares of its common stock in exchange for $5 million in principal amount of its Convertible Senior Notes due in 2027, leveraging an exemption under the Securities Act for this transaction.

Tilray Approves Reverse Stock Split Proposal

On June 10, 2025, Tilray Brands, Inc. held a special meeting of stockholders to vote on two proposals: an amendment for a reverse stock split and the adjournment of the meeting for further proxy solicitation if needed. Both proposals were approved, with the board retaining discretion on executing the reverse stock split, indicating a strategic move to potentially enhance the company’s stock market positioning.